Antifungal and antiparasitic compounds

Compounds are described which represent novel, efficacious, and less toxic alternatives to current antiparasitic/antifungal treatments. Compounds having action via the biochemical mechanism of inhibition of lipid synthesis and/or metabolism and/or excretion, either by direct or indirect inhibition, will have either singly or in combination antiparasite/antifungal activity. Such compounds, in most cases, are not chemically related by structure or chemical class to each other. The compounds are identified as antiparasitics and/or antifungals based on mechanism of physiologic action. Data supporting "novel use" as antiparasite/antifungal compounds are given. Many compounds herein described are FDA-approved and marketed for human use for nonparasitic/nonfungal indications. Thus, the human pharmacokinetics for oral absorption, elimination rates/mechanisms, and dose-related toxicity are known. Novel antiparasitic and antifungal compositions are disclosed. The antiparasitic and antifungal compositions are useful for human and veterinary therapy for the treatment and/or prevention of parasitic infection. Also disclosed are novel mechanisms of identifying antifungal and antiparasitic compositions by their biochemical action on lipid synthesis and/or metabolism and/or excretion.